Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsEventsSponsored PodcastsSponsored VideosWebcastsWhitepaperseBooks
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Peter Madrid

Advertisement

Articles by Peter Madrid

Image credit: AndSus | stock.adobe.com. Circuit board in shape electronic brain with gyrus, symbol ai hanging over hand. Symbol of computer neural networks or artificial intelligence in neon cyberspace with glowing title on palm scientist

The Promise and Peril of AI in the Physical World

ByPeter Madrid
February 9th 2024

The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics

    2

    How Pharma Workflows Are Impacted by Agentic Models Beyond Productivity Gains

    3

    The Hidden Risk in Pharma’s AI Rush

    4

    FDA Approves Cosentyx for Polymyalgia Rheumatica, Wilserdly for ER-Positive ESR1-Mutated Advanced Breast Cancer

    5

    Pharmaceutical Executive Daily: FDA Approves Three New Therapies

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us